RxDoctor Payments Data

Allison Scott

Family · Lumberton, NCNPI 1629363122

Payments from drug & device makers

$2,770in general payments, 2019–2025

Across 118 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$369
  • Novo Nordisk$337
  • Bayer$330
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$255
  • Amgen$191
  • Johnson & Johnson$187
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,770 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,986
Medicare patients
182
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban219$189,950
EntrestoSacubitril/Valsartan133$134,453
Repatha SureclickEvolocumab68$72,513
JardianceEmpagliflozin49$53,189
XareltoRivaroxaban60$48,364
BrilintaTicagrelor45$25,677
VerquvoVericiguat16$13,294
FarxigaDapagliflozin Propanediol14$7,845
Repatha SyringeEvolocumab11$5,843
Ranolazine ErRanolazine70$4,834
Metoprolol Succinate330$3,316
Atorvastatin Calcium255$1,977
Clonidine22$1,756
Rosuvastatin Calcium149$1,667
Isosorbide Mononitrate ErIsosorbide Mononitrate221$1,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$189,950219 claims
NovartisEntresto$136$134,453133 claims
Boehringer IngelheimJardiance$174$53,18949 claims
Johnson & JohnsonXarelto$187$48,36460 claims
AstraZenecaBrilinta, Farxiga$105$33,52259 claims
MerckVerquvo$369$13,29416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.

Other family in Lumberton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →